Equity and access to neurotechnology
The distributive-justice dimension: who bears the risks and who receives the benefits of neurotech. Concerns span cost and reimbursement (implants and their upkeep are expensive), global access gaps, the representation of disabled people in design and governance ('nothing about us without us'), and the risk that enhancement technologies widen existing inequalities.
Equity also concerns the early recipients themselves. Trial participants take on the risks of first-generation implants; fairness demands attention to their long-term care and to whether benefits reach beyond wealthy health systems rather than concentrating there.
Equity is where governance meets economics: rights on paper mean little if only a few can access safe, maintained devices. The access question is inseparable from post-trial obligations and from the risk of abandoned implants.